Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial

Association with hypomethylating agents is a promising strategy to improve the efficacy of immune checkpoint inhibitors-based therapy. The NIBIT-M4 was a phase Ib, dose-escalation trial in patients with advanced melanoma of the hypomethylating agent guadecitabine combined with the anti-CTLA-4 antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: Noviello, Teresa Maria Rosaria, Di Giacomo, Anna Maria, Caruso, Francesca Pia, Covre, Alessia, Mortarini, Roberta, Scala, Giovanni, Costa, Maria Claudia, Coral, Sandra, Fridman, Wolf H., Sautès-Fridman, Catherine, Brich, Silvia, Pruneri, Giancarlo, Simonetti, Elena, Lofiego, Maria Fortunata, Tufano, Rossella, Bedognetti, Davide, Anichini, Andrea, Maio, Michele, Ceccarelli, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516894/
https://www.ncbi.nlm.nih.gov/pubmed/37739939
http://dx.doi.org/10.1038/s41467-023-40994-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516894/
https://www.ncbi.nlm.nih.gov/pubmed/37739939
http://dx.doi.org/10.1038/s41467-023-40994-4

Ejemplares similares